BE1116 + FFP

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Complex Cardiovascular Surgery With Cardiopulmonary Bypass

Conditions

Complex Cardiovascular Surgery With Cardiopulmonary Bypass

Trial Timeline

Sep 15, 2025 → Dec 17, 2026

NCT ID

NCT07094087

About BE1116 + FFP

BE1116 + FFP is a phase 3 stage product being developed by CSL for Complex Cardiovascular Surgery With Cardiopulmonary Bypass. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07094087. Target conditions include Complex Cardiovascular Surgery With Cardiopulmonary Bypass.

What happened to similar drugs?

7 of 18 similar drugs in Complex Cardiovascular Surgery With Cardiopulmonary Bypass were approved

Approved (7) Terminated (4) Active (9)

✅clarithromycin, rifabutinPfizerApproved

✅Pregabalin + PregabalinPfizerApproved

✅AzithromycinPfizerApproved

✅Azithromycin + Rifabutin/rifampinPfizerApproved

✅vigabatrinLundbeckApproved

✅SabrilLundbeckApproved

✅Cannabidiol Oral Solution [Epidiolex]Jazz PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07094087	Phase 3	Recruiting	Sep 15, 2025	Dec 17, 2026	Complex Cardiovascular Surgery With Cardiopulmonary Bypass

Competing Products

20 competing products in Complex Cardiovascular Surgery With Cardiopulmonary Bypass

See all competitors

Product	Company	Stage	Hype Score
Zonisamide	Eisai	Phase 3	40
Eslicarbazepine acetate + Eslicarbazepine acetate	Sumitomo Pharma	Phase 3	40
Everolimus (RAD001) + Everolimus Placebo	Novartis	Phase 3	40
Zoledronic acid + Placebo	Novartis	Phase 2	31
RAD001 + Placebo	Novartis	Phase 2	35
RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)	Novartis	Phase 3	40
everolimus	Novartis	Phase 3	44
ranolazine	Gilead Sciences	Phase 2	35
clarithromycin, rifabutin	Pfizer	Approved	43
Pregabalin + Pregabalin	Pfizer	Approved	35
Pregabalin	Pfizer	Pre-clinical	18
Azithromycin	Pfizer	Approved	43
Azithromycin + Rifabutin/rifampin	Pfizer	Approved	43
Stavudine	Bristol Myers Squibb	Phase 3	40
Zidovudine + Didanosine	Bristol Myers Squibb	Phase 2	35
Haemocomplettan® P + Human albumin (Placebo)	CSL	Phase 2/3	38
CSL730 + Placebo	CSL	Phase 1	21
vigabatrin	Lundbeck	Approved	32
Sabril	Lundbeck	Approved	40
GWP42003-P	Jazz Pharmaceuticals	Phase 3	29